ORCID Profile
0000-0001-9810-1982
Current Organisation
Hashemite University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: International Union of Crystallography (IUCr)
Date: 15-08-2007
Publisher: International Union of Crystallography (IUCr)
Date: 13-11-2008
Publisher: MDPI AG
Date: 09-01-2023
Abstract: 2′,3,3,5′-Tetramethyl-4′-nitro-2′H-1,3′-bipyrazole (TMNB) is a novel bipyrazole compound with unknown therapeutic potential in diabetes mellitus. This study aims to investigate the anti-diabetic effects of TMNB in a high-fat diet and streptozotocin-(HFD/STZ)-induced rat model of type 2 diabetes mellitus (T2D). Rats were fed HFD, followed by a single low dose of STZ (40 mg/kg). HFD/STZ diabetic rats were treated orally with TMNB (10 mg/kg) or (200 mg/kg) metformin for 10 days before terminating the experiment and collecting plasma, soleus muscle, adipose tissue, and liver for further downstream analysis. TMNB reduced the elevated levels of serum glucose in diabetic rats compared to the vehicle control group (p 0.001). TMNB abrogated the increase in serum insulin in the treated diabetic group compared to the vehicle control rats (p 0.001). The homeostasis model assessment of insulin resistance (HOMA-IR) was decreased in the diabetic rats treated with TMNB compared to the vehicle controls. The skeletal muscle and adipose tissue protein contents of GLUT4 and AMPK were upregulated following treatment with TMNB (p 0.001, 0.01, respectively). TMNB was able to upregulate GLUT2 and AMPK protein expression in liver (p 0.001, 0.001, respectively). LDL, triglyceride, and cholesterol were reduced in diabetic rats treated with TMNB compared to the vehicle controls (p 0.001, 0.01, respectively). TMNB reduced MDA and IL-6 levels (p 0.001), and increased GSH level (p 0.05) in diabetic rats compared to the vehicle controls. Conclusion: TMNB ameliorates insulin resistance, oxidative stress, and inflammation in a T2D model. TMNB could represent a promising therapeutic agent to treat T2D.
Publisher: Informa UK Limited
Date: 23-08-2023
Publisher: Elsevier BV
Date: 08-2021
Publisher: Royal Society of Chemistry (RSC)
Date: 2020
DOI: 10.1039/D0NJ03105D
Abstract: An N -(cyano(naphthalen-1-yl)methyl)benzamide derivative was developed as a colorimetric sensor that shows a dramatic colorless-to-black response to fluoride anions.
Publisher: Springer Science and Business Media LLC
Date: 28-05-2014
Publisher: International Union of Crystallography (IUCr)
Date: 21-09-2007
No related grants have been discovered for Kayed Abu- Safieh.